FutureChem Co., Ltd.
FutureChem is a KOSDAQ-listed (220100) radiopharmaceutical company based in Seoul. Its PSMA-targeted therapy FC705 (ludotadipep) is in Phase 3 in South Korea, alongside the commercial diagnostic FC303.
| Headquarters | Seoul, South Korea |
|---|---|
| Listing | KOSDAQ:220100 |
| Lead asset / stage | FC705 (ludotadipep) Phase 3 — South Korea |
| Latest event | FutureChem issued a shareholder update on FC705 clinical development and FC303 commercialization. |